- Details
- Description
-
Packaging Size30t/bottle
-
Strength200mg
-
CompositonBelumosudil
-
Treatmentchronic graft versus host disease (cGvHD)
-
FormTablet
-
BrandLucibelu
-
Quantity Unit200mg*30t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Belumosudil
Belumosudil is a medication used for the treatment of chronic graft versus host disease (cGvHD).It is in the class of drugs known as serine/threonine kinase inhibitors. Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II).ROCK2-mediated signaling pathways are major players in pro- and anti-inflammatory immune cell responses. A study in cultured human cells demonstrated that the drug also has effects on oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling.
Graft Versus Host Disease
Indicated for chronic graft versus host disease (GVHD) in adults and adolescents aged ≥12 years after failure of at least 2 prior lines of systemic therapy
200 mg PO qDay
Continue until progression of chronic GVHD requires new systemic therapy
Dosage Modifications
Hepatotoxicity
- Grade 3 AST or ALT (5-20x ULN) or Grade 2 bilirubin (1.5-3x ULN): Hold until recovery of bilirubin, AST, and ALT to Grade 0-1, then resume at recommended dose
- Grade 4 AST or ALT (>20x ULN) or Grade ≥3 bilirubin (>3x ULN): Permanently discontinue
Other adverse reactions
- Grade 3: Hold until recovery to Grade 0-1, then resume at recommended dose level
- Grade 4: Permanently discontinue
Renal impairment
- Mild-to-moderate (≥30 to <90 mL/min/1.72 m2): No dosage adjustment necessary
- Severe (<30 mL/min/1.72 m2): Not studied
- Patients with preexisting severe renal impairment: Not studied; consider risks and potential benefits before initiating treatment
Hepatic impairment
- Mild Hepatic impairment (Child-Pugh A): No dosage adjustment recommended
- Moderate or severe hepatic impairment IChild-Pugh B or C): Avoid use
Strong CYP3A4 inducers
- If coadministered, increase to 200 mg PO BID
Proton pump inhibitors
- If coadministered, increase to 200 mg PO BID
